These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15464916)

  • 1. Donor lymphocyte infusions.
    Ho VT; Alyea EP
    Adv Pharmacol; 2004; 51():319-45. PubMed ID: 15464916
    [No Abstract]   [Full Text] [Related]  

  • 2. Donor lymphocyte infusions for hematopoietic malignancy.
    Slavin S
    Cancer Chemother Biol Response Modif; 2002; 20():291-9. PubMed ID: 12703210
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoptive immunotherapy:insights from donor lymphocyte infusions.
    Alyea E
    Transfusion; 2000 Apr; 40(4):393-5. PubMed ID: 10773047
    [No Abstract]   [Full Text] [Related]  

  • 4. Alpha interferon augments the graft-versus-leukaemia effect of second stem cell transplants and donor lymphocyte infusions in high-risk paediatric leukaemias.
    Cooper N; Rao K; Goulden N; Amrolia P; Veys P
    Br J Haematol; 2012 Feb; 156(4):550-2. PubMed ID: 21981646
    [No Abstract]   [Full Text] [Related]  

  • 5. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic HPC transplantation.
    Baron F; Beguin Y
    Transfusion; 2000 Apr; 40(4):468-76. PubMed ID: 10773061
    [No Abstract]   [Full Text] [Related]  

  • 6. Donor leukocyte infusions in myeloid malignancies: new strategies.
    Porter DL; Antin JH
    Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-A*0201 is associated with a better outcome after donor lymphocyte infusion for recurrent malignancy.
    Nachbaur D; Angelova O; Loacker K; Auberger J; Clausen J; Schumacher P; Gastl G; Kircher B
    Eur J Haematol; 2009 Jan; 82(1):77-8. PubMed ID: 18801059
    [No Abstract]   [Full Text] [Related]  

  • 9. Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.
    Du B; Li DP; Xu KL; Pan XY
    Chin Med J (Engl); 2005 Mar; 118(6):474-9. PubMed ID: 15788128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion.
    Levenga H; Woestenenk R; Schattenberg AV; Maas F; Jansen JH; Raymakers R; De Mulder PH; van de Wiel-van Kemenade E; Schaap N; de Witte T; Dolstra H
    Bone Marrow Transplant; 2007 Sep; 40(6):585-92. PubMed ID: 17637687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses to donor lymphocyte infusion for acute lymphoblastic leukemia may be determined by both qualitative and quantitative limitations of antileukemic T-cell responses as observed in an animal model for human leukemia.
    Nijmeijer BA; van Schie ML; Verzaal P; Willemze R; Falkenburg JH
    Exp Hematol; 2005 Oct; 33(10):1172-81. PubMed ID: 16219539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation.
    Loren AW; Porter DL
    Bone Marrow Transplant; 2008 Mar; 41(5):483-93. PubMed ID: 18026156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temporal discordance between graft-versus-leukemia and graft-versus-host responses: a strategy for the separation of graft-versus-leukemia/graft-versus-host reactivity?
    Hari P; Logan B; Drobyski WR
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):743-7. PubMed ID: 15505605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Possibility of selective induction of a GVL effect without increasing GVHD].
    Akatsuka Y
    Rinsho Ketsueki; 2008 Aug; 49(8):607-15. PubMed ID: 18800609
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecules and mechanisms of the graft-versus-leukaemia effect.
    Bleakley M; Riddell SR
    Nat Rev Cancer; 2004 May; 4(5):371-80. PubMed ID: 15122208
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.
    El-Jurdi N; Reljic T; Kumar A; Pidala J; Bazarbachi A; Djulbegovic B; Kharfan-Dabaja MA
    Immunotherapy; 2013 May; 5(5):457-66. PubMed ID: 23638742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.
    Loren AW; Porter DL
    Curr Opin Oncol; 2006 Mar; 18(2):107-14. PubMed ID: 16462177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation.
    Blair A; Goulden NJ; Libri NA; Oakhill A; Pamphilon DH
    Blood Rev; 2005 Nov; 19(6):289-300. PubMed ID: 16275419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of donor lymphocyte infusion: how to improve the outcome?
    Wang Y; Xu L; Yan C; Huang X
    Sci China Life Sci; 2019 Sep; 62(9):1253-1256. PubMed ID: 31372818
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.